Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?

ABSTRACT:

Background and objectives

This study describes preferences of German relapsed refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based combination treatments.

Methods

Patients with a minimum age of 18 years and a diagnosis of RRMM were included. Their preferences were assessed using a discrete choice experiment design, which was developed based on a literature review and two patient focus group discussions. The final discrete choice experiment design consisted of four attributes, namely "therapy application regimen," "time without progression of disease," "possibility of grade ≥3 adverse events (AEs) affecting the blood," and "possibility of grade ≥3 AE heart failure."

Results

Analysis was based on 84 patients (36.9% females, mean age 62.7 yea

SUBMITTER: Wilke T 

PROVIDER: S-EPMC6235009 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature